The Combined Effect of Silybum marianum, Cynara scolymus, Curcuma longa and Taraxacum officinale extracts on fatty liver

The Combined Effect of Silybum marianum, Cynara scolymus, Curcuma longa and Taraxacum officinale extracts on metabolic parameters, oxidative stress biomarkers and inflammation in patients with Non-alcoholic fatty liver disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170430033730N2

Enrollment

Registered

2018-07-02

Start date

2018-06-20

Completion date

Unknown

Last updated

2018-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-alcoholic fatty liver. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: Intervention group: Two capsules of 275 mg of combined extract were taken twice daily for twelve weeks. Intervention 2: Control group: Two capsules of 275 mg of placebo were taken twi

Eligibility

Sex/Gender

All

Age

30 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients with Non-alcoholic fatty liver disease

Exclusion criteria

Exclusion criteria: patients who do not want to cooperate People who smoke People who drink alcohol Patients with gastrointestinal disorders Patients who take nerve medications Diabetic Patients

Design outcomes

Primary

Measure	Time frame
FBS. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;Insulin. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: ELISA.	—

Secondary

Measure	Time frame
TG. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;Cholesterol. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;HDL. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;LDL. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;AST. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;ALT. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;Glutathion. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;MDA. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;IL-1. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: ELISA.;TNF-a. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: ELISA.	—

Measure

Time frame

TG. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;Cholesterol. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;HDL. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;LDL. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;AST. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;ALT. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;Glutathion. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;MDA. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;IL-1. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: ELISA.;TNF-a. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: ELISA.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyyed Mehdi Mirhashemi

Qazvin University of Medical Sciences

mirhashemism@gmail.com+98 28 3333 6001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026